1
|
Gromova OA, Torshin IY, Lila AM. On the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritis. NEUROLOGY, NEUROPSYCHIATRY, PSYCHOSOMATICS 2022. [DOI: 10.14412/2074-2711-2022-6-122-130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- O. A. Gromova
- Institute of Pharmacoinformatics of the Federal Research Center “Computer Science and Management”, Russian Academy of Sciences
| | - I. Y. Torshin
- Institute of Pharmacoinformatics of the Federal Research Center “Computer Science and Management”, Russian Academy of Sciences
| | - A. M. Lila
- V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
| |
Collapse
|
2
|
Wu M, Cai J, Yu Y, Hu S, Wang Y, Wu M. Therapeutic Agents for the Treatment of Temporomandibular Joint Disorders: Progress and Perspective. Front Pharmacol 2021; 11:596099. [PMID: 33584275 PMCID: PMC7878564 DOI: 10.3389/fphar.2020.596099] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 11/19/2020] [Indexed: 02/05/2023] Open
Abstract
Temporomandibular joint disorders (TMD) are a common health condition caused by the structural or functional disorders of masticatory muscles and the temporomandibular joint (TMJ). Abnormal mandibular movement in TMD patients may cause pain, chronic inflammation, and other discomfort, which could be relieved by a variety of drugs through various delivery systems. In this study, we summarized commonly used therapeutic agents in the management of TMD as well as novel bioactive molecules in preclinical stage and clinical trials. The emerging therapy strategies such as novel intra-TMJ delivery systems and implants based on tissue engineering are also discussed. This comprehensive review will strengthen our understanding of pharmacological approaches for TMD therapy.
Collapse
Affiliation(s)
- Mengjie Wu
- The Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, and Key Laboratory of Oral Biomedical Research of Zhejiang Province, Hangzhou, China
| | - Jingyi Cai
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Orthodontics, West China Hospital of Stomato-logy, Sichuan University, Chengdu, China
| | - Yeke Yu
- Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Sihui Hu
- The Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, and Key Laboratory of Oral Biomedical Research of Zhejiang Province, Hangzhou, China
| | - Yingnan Wang
- The Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, and Key Laboratory of Oral Biomedical Research of Zhejiang Province, Hangzhou, China
| | - Mengrui Wu
- College of Life Sciences, Zhejiang University, Zhejiang, China
| |
Collapse
|
3
|
Sellam J, Courties A, Eymard F, Ferrero S, Latourte A, Ornetti P, Bannwarth B, Baumann L, Berenbaum F, Chevalier X, Ea HK, Fabre MC, Forestier R, Grange L, Lellouche H, Maillet J, Mainard D, Perrot S, Rannou F, Rat AC, Roux CH, Senbel E, Richette P. Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis. Joint Bone Spine 2020; 87:548-555. [PMID: 32931933 DOI: 10.1016/j.jbspin.2020.09.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVES To establish recommendations for pharmacological treatment of knee osteoarthritis specific to France. METHODS On behalf of the French Society of Rheumatology (SFR), a bibliography group analyzed the literature on the efficacy and safety of each pharmacological treatment for knee osteoarthritis. This group joined a multidisciplinary working group to draw up recommendations. Strength of recommendation and quality of evidence level were assigned to each recommendation. A review committee gave its level of agreement. RESULTS Five general principles were established: 1) need to combine pharmacological and non-pharmacological treatments, 2) personalization of treatment, 3) symptomatic and/or functional aim of pharmacological treatments, 4) need to regularly re-assess the treatments and 5) discussion about arthroplasty if medical treatment fails. Six recommendations involved oral treatments: 1) paracetamol should not necessarily be prescribed systematically and/or continuously, 2) NSAIDs, possibly as first-line, 3) weak opioids, 4) strong opioids, 5) symptomatic slow-acting drugs of osteoarthritis, and 6) duloxetine (off-label use). Two recommendations involved topical agents (NSAIDs and capsaicin<1%). Three recommendations involved intra-articular treatments: corticosteroid or hyaluronic acid injections that can be proposed to patients. The experts did not draw a conclusion about the benefits of platelet-rich plasma injections. CONCLUSION These are the first recommendations of the SFR on the pharmacological treatment of knee osteoarthritis.
Collapse
Affiliation(s)
- Jérémie Sellam
- Service de rhumatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Antoine, Sorbonne Université, Inserm UMRS_938, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
| | - Alice Courties
- Service de rhumatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Antoine, Sorbonne Université, Inserm UMRS_938, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France
| | - Florent Eymard
- Service de rhumatologie, Hôpital Henri Mondor, AP-HP, 94000 Créteil, France
| | - Stéphanie Ferrero
- Service de rhumatologie, LAMHESS, université Cote d'Azur, CHU de Nice, 06000 Nice, France
| | - Augustin Latourte
- Service de rhumatologie, hôpital Lariboisière, AP-HP, 75010 Paris, France
| | - Paul Ornetti
- Service de rhumatologie, CHU de Dijon, 21000 Dijon, France
| | | | | | - Francis Berenbaum
- Service de rhumatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Antoine, Sorbonne Université, Inserm UMRS_938, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France
| | - Xavier Chevalier
- Service de rhumatologie, Hôpital Henri Mondor, AP-HP, 94000 Créteil, France
| | - Hang Korng Ea
- Service de rhumatologie, hôpital Lariboisière, AP-HP, 75010 Paris, France
| | | | - Romain Forestier
- Centre de recherche rhumatologique et thermale, 73100 Aix-les-Bains, France
| | - Laurent Grange
- Service de rhumatologie, AFLAR, CHU de Grenoble-Alpes, 38000 Grenoble/Paris, France
| | - Henri Lellouche
- Cabinet libéral et service de rhumatologie, hôpital Lariboisière, AP-HP, 75010 Paris, France
| | - Jérémy Maillet
- Service de rhumatologie, hôpital Lariboisière, AP-HP, 75010 Paris, France
| | - Didier Mainard
- Service de chirurgie orthopédique, CHU de Nancy, 54000 Nancy, France
| | - Serge Perrot
- Centre d'évaluation et traitement de la douleur, hôpital Cochin, AP-HP, 75014 Paris, France
| | - François Rannou
- Service de rééducation et de réadaptation de l'appareil locomoteur et des pathologies du Rachis, centre-université de Paris, hôpital Cochin, université de Paris, AP-HP, 75014 Paris, France
| | | | - Christian H Roux
- Service de rhumatologie, LAMHESS, université Cote d'Azur, CHU de Nice, 06000 Nice, France
| | - Eric Senbel
- Cabinet libéral et service de rhumatologie, Hôpital Sainte-Marguerite, 13000, Marseille, France
| | - Pascal Richette
- Service de rhumatologie, hôpital Lariboisière, AP-HP, 75010 Paris, France
| | -
- Faculté de santé, UFR médecine de Paris-Centre, 75006 Paris, France
| |
Collapse
|
4
|
Isaacs RB, Hellberg RS. Shark Cartilage Supplement Labeling Practices and Compliance with U.S. Regulations. J Diet Suppl 2019; 18:44-56. [PMID: 31809613 DOI: 10.1080/19390211.2019.1698687] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The objective of this study was to analyze labeling practices and compliance with regulatory standards for shark cartilage supplements sold in the United States. The product labels of 29 commercial shark cartilage supplements were assessed for compliance with U.S. regulations. Claims, including nutrient content, prohibited disease, and nutritional support statements, were examined for compliance and substantiation. Overall, 48.3% of the samples had at least one instance of noncompliance with labeling regulations. The most common labeling violations observed were: missing a domestic address/phone number, non-compliant nutrient content claim, missing/incomplete disclaimer, missing statement of identity, prohibited disease claims, and incomplete "Supplement Facts" label. The use of prohibited disease claims and nutritional support statements without the required disclaimer is concerning from a public health standpoint because consumers may delay seeking professional treatment for a disease. The results of this study indicate a need for improved labeling compliance among shark cartilage supplements.
Collapse
Affiliation(s)
- Rachel B Isaacs
- Schmid College of Science and Technology, Food Science Program, Chapman University, Orange, CA, USA
| | - Rosalee S Hellberg
- Schmid College of Science and Technology, Food Science Program, Chapman University, Orange, CA, USA
| |
Collapse
|
5
|
Coimbra IB, Plapler PG, de Campos GC. Generating evidence and understanding the treatment of osteoarthritis in Brazil: a study through Delphi methodology. Clinics (Sao Paulo) 2019; 74:e722. [PMID: 31090795 PMCID: PMC6536090 DOI: 10.6061/clinics/2019/e722] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 01/09/2019] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVES This study aimed to provide evidence for understanding how to treat osteoarthritis (OA) in our country. Therefore, it was necessary to match information and investigations related to the treatment of the disease from the three main types of specialists involved: physiatrists, orthopedists and rheumatologists. METHODS The authors acted as a scientific advisory committee. From the initial discussions, a structured questionnaire was developed for use with a group of specialists on OA using the Delphi technique. The questionnaire was sent to 21 experts appointed by the authors, and the results obtained were critically analyzed and validated. RESULTS The prevalence of OA was 33% in Brazil, corresponding to one-third of the individuals in the reference population, which included individuals over 25 years of age. Another significant finding was that most patients did not receive any form of treatment in the early stages of OA. CONCLUSION The committee pointed to the need for early intervention and that the available medicinal resources can fulfil this important role, as is the case with SYSADOA treatments. Glucosamine-based medicinal products with or without chondroitin could also fulfill this need for early treatment. The other generated evidence and included investigations were then grouped together and are the subject of this publication.
Collapse
Affiliation(s)
- Ibsen Bellini Coimbra
- Disciplina de Reumatologia, Departamento de Clinica Medica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, SP, BR
| | - Pérola Grinberg Plapler
- Instituto de Ortopedia e Traumatologia, Departamento de Fisiologia, Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo, SP, BR
- Corresponding author. E-mail:
| | | |
Collapse
|
6
|
Torshin IY, Gromova OA, Lila AM, Naumov AV, Sorokina MA, Rudakov KV. The results of postgenomic analysis of a glucosamine sulfate molecule indicate the prospects of treatment for comorbidities. MODERN RHEUMATOLOGY JOURNAL 2018. [DOI: 10.14412/1996-7012-2018-4-129-136] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- I. Yu. Torshin
- Institute of Pharmacoinformatics, Federal Research Center «Informatics and Control», Russian Academy of Sciences
| | - O. A. Gromova
- Institute of Pharmacoinformatics, Federal Research Center «Informatics and Control», Russian Academy of Sciences
| | - A. M. Lila
- V.A. Nasonova Research Institute of Rheumatology
| | - A. V. Naumov
- Russian Gerontology Research and Clinical Center
| | - M. A. Sorokina
- Dmitry Rogachev Federal Research and Clinical Center for Pediatric Hematology, Oncology, and Immunology
| | - K. V. Rudakov
- Institute of Pharmacoinformatics, Federal Research Center «Informatics and Control», Russian Academy of Sciences
| |
Collapse
|
7
|
Oral Glucosamine Hydrochloride Combined With Hyaluronate Sodium Intra-Articular Injection for Temporomandibular Joint Osteoarthritis: A Double-Blind Randomized Controlled Trial. J Oral Maxillofac Surg 2018; 76:2066-2073. [PMID: 29864430 DOI: 10.1016/j.joms.2018.04.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 04/22/2018] [Accepted: 04/23/2018] [Indexed: 02/05/2023]
Abstract
PURPOSE Temporomandibular joint (TMJ) disorders occur in many people and osteoarthritis (OA) is a severe form of this disease. Glucosamine has been used to treat OA of the large joints for many years and has been proved effective. A double-blinded randomized controlled trial was designed to investigate the effectiveness and safety of oral glucosamine hydrochloride pills combined with hyaluronate sodium intra-articular injection in TMJ OA. PATIENTS AND METHODS One hundred forty-four participants with TMJ OA were randomized to 4 hyaluronate sodium injections and oral glucosamine hydrochloride (1.44 g/day) for 3 months (group A) or 4 hyaluronate sodium injections and oral placebo for 3 months (group B). All participants were followed for 1 year. Eighteen participants were lost to follow-up. RESULTS The intention-to-treat analysis showed that group A had similar maximal interincisal mouth opening and pain intensity during TMJ function at months 1 and 6 (P > .05). However, during long-term follow-up, group A had significantly greater maximal interincisal mouth opening compared with group B at month 12 (41.5 vs 37.9 mm; P < .001). For pain intensity, group A showed obviously lower visual analog scale scores than group B at month 6 (20.6 vs 29.2 mm; P = .007) and month 12 (17.4 vs 28.6 mm; P = .001). Twenty-four participants had gastrointestinal tract side effects, fatigue, and rash. Of these, 23 had slight side effects that were not correlated with glucosamine. There was no significant difference between the 2 groups (P > .05). CONCLUSION The results of this study suggest that, compared with hyaluronate sodium injection alone, glucosamine hydrochloride pills added to hyaluronate sodium injection had no meaningful effect on TMJ OA in the short-term but did relieve the pain caused by TMJ OA and improved TMJ functions in the long-term.
Collapse
|
8
|
Liu X, Eyles J, McLachlan AJ, Mobasheri A. Which supplements can I recommend to my osteoarthritis patients? Rheumatology (Oxford) 2018; 57:iv75-iv87. [PMID: 29506080 DOI: 10.1093/rheumatology/key005] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Indexed: 01/07/2023] Open
Abstract
OA is a chronic and disabling joint disease with limited evidence-based pharmacological treatment options available that improve outcomes for patients safely. Faced with few effective pharmacological treatments, the use has grown of dietary supplements and complementary medicines for symptomatic relief among people living with OA. The aim of this review is to provide a summary of existing evidence and recommendations supporting the use of supplements for OA. Systematic reviews and randomized controlled trials investigating oral supplements for treating OA were identified. Limited research evidence supports recommendations for the oral use of Boswellia serrata extract and Pycnogenol, curcumin and methylsulfonylmethane in people with OA despite the poor quality of the available studies. Few studies adequately reported possible adverse effects related to supplementation, although the products were generally recognized as safe. Further high quality trials are needed to improve the strength of evidence to support this recommendation and better guide optimal treatment of people living with OA.
Collapse
Affiliation(s)
- Xiaoqian Liu
- Rheumatology Department, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia.,Institute of Bone and Joint Research, the Kolling Institute, The University of Sydney, Sydney, NSW, Australia
| | - Jillian Eyles
- Rheumatology Department, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia.,Institute of Bone and Joint Research, the Kolling Institute, The University of Sydney, Sydney, NSW, Australia.,Physiotherapy Department, Royal North Shore Hospital, Sydney, NSW, Australia
| | - Andrew J McLachlan
- Faculty of Pharmacy and Centre for Education and Research in Ageing, The University of Sydney and Concord Hospital, Sydney, NSW, Australia
| | - Ali Mobasheri
- Department of Veterinary Preclinical Sciences, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK.,Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Queen's Medical Centre, Nottingham, UK
| |
Collapse
|
9
|
McCarty MF, O'Keefe JH, DiNicolantonio JJ. Glucosamine for the Treatment of Osteoarthritis: The Time Has Come for Higher-Dose Trials. J Diet Suppl 2018; 16:179-192. [PMID: 29667462 DOI: 10.1080/19390211.2018.1448920] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Although clinical trials with glucosamine in osteoarthritis have yielded mixed results, leading to doubts about its efficacy, the utility of glucosamine for preventing joint destruction and inflammation is well documented in rodent models of arthritis, including models of spontaneous osteoarthritis. The benefit of oral glucosamine in adjuvant arthritis is markedly dose dependent, likely reflecting a modulation of tissue levels of UDP-N-acetylglucosamine that in turn influences mucopolysaccharide synthesis and the extent of protein O-GlcNAcylation. Importantly, the minimal oral dose of glucosamine that exerts a detectible benefit in adjuvant arthritis achieves plasma glucosamine levels similar to those achieved when the standard clinical dose of glucosamine, 1.5 g daily, is administered as a bolus. The response of plasma glucosamine levels to an increase in glucosamine intake is nearly linear. Remarkably, every published clinical trial with glucosamine has employed the same 1.5 g dose that Rottapharm recommended for its proprietary glucosamine sulfate product decades ago, yet there has never been any published evidence that this dose is optimal with respect to efficacy and side effects. If this dose is on the edge of demonstrable clinical efficacy when experimental design is ideal, then variations in the patient populations targeted, the assessment vehicles employed, and the potency of glucosamine preparations tested could be expected to yield some null results. Failure to employ bolus dosing may also be a factor in the null results observed in the GAIT study and other trials. Clinical studies evaluating the dose dependency of glucosamine's influence on osteoarthritis are long overdue.
Collapse
Affiliation(s)
| | - James H O'Keefe
- b Mid America Heart Institute , University of Missouri-Kansas City , Kansas City , MO , USA
| | | |
Collapse
|
10
|
Abstract
Joint pain due to osteoarthritis (OA) is often severe and disabling and affects a large proportion of the aging population impairing daily living and quality of life. Numerous pharmacological treatment approaches are available. Including major OA guidelines this review presents the current evidence of pharmacological therapies in OA-related pain and covers topical, oral and intraarticular treatment approaches. In patients with mild OA topical nonsteroidal antiinflammatory drugs (NSAIDs) can be recommended. Topical capsaicin can be used when other treatments are ineffective or contraindicated. In patients with moderate to severe OA oral NSAIDs are suggested at the lowest effective dose for the shortest possible duration to control symptoms. Importantly, drug-related side effects and gastrointestinal, cardiovascular and renal comorbidities need to be taken into account. In patients with multiple-joint OA and high risk of NSAID-induced adverse events duloxetine can be considered. The evidence of metamizole, symptomatic slow-acting drugs in osteoarthritis and other nutritional supplements in the treatment of OA pain is uncertain and the use of opioids is not routinely recommended. In patients suffering from severe OA-related pain intraarticular injections with glucocorticoids can be suggested to achieve short-term pain relief. Evidence for interventional approaches using hyaluronic acid or platelet-rich plasma is uncertain. Yet, the efficacy of pharmacological therapies in OA-related pain is often inconsistent and severe adverse events might occur. Thus, critical use of the different treatment options considering patient-related comorbidities and nonpharmacological therapies is of major importance.
Collapse
Affiliation(s)
- T A Nees
- Klinik für Orthopädie und Unfallchirurgie, Zentrum für Orthopädie, Unfallchirurgie und Paraplegiologie, Universitätsklinikum Heidelberg, Schlierbacher Landstraße 220a, 69118, Heidelberg, Deutschland.
| | - M Schiltenwolf
- Klinik für Orthopädie und Unfallchirurgie, Zentrum für Orthopädie, Unfallchirurgie und Paraplegiologie, Universitätsklinikum Heidelberg, Schlierbacher Landstraße 220a, 69118, Heidelberg, Deutschland
| |
Collapse
|
11
|
Cen X, Liu Y, Wang S, Yang X, Shi Z, Liang X. Glucosamine oral administration as an adjunct to hyaluronic acid injection in treating temporomandibular joint osteoarthritis. Oral Dis 2017; 24:404-411. [PMID: 28862770 DOI: 10.1111/odi.12760] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2017] [Revised: 07/28/2017] [Accepted: 08/10/2017] [Indexed: 02/05/2023]
Abstract
OBJECTIVE To investigate the therapeutic effect of oral glucosamine (GS) as an adjunct to hyaluronic acid (HA) injection on patients with temporomandibular joint osteoarthritis (TMJ OA). METHODS In this clinical trial, 136 participants, diagnosed as TMJ OA clinically and radiographically, were enrolled and randomized into two groups (group GS + HA: oral GS + HA injection; group placebo + HA: oral placebo + HA injection). Pain, maximum interincisal mouth opening (MMO), the levels of IL-1β, IL-6, and TGF-β in TMJ synovial were defined as the outcome measurements and conducted before operation, and at 1-month and 1-year follow-up. RESULTS In both groups, pain scores were decreased and MMOs were increased at 1-month and 1-year follow-up, the changes at 1-year follow-up showed statistically significant intergroup differences. At 1-month follow-up, only IL-6 concentration was lower in group GS + HA than that in group placebo + HA. One year later, TGF-β concentration was higher and IL-6 and IL-1β concentrations were lower in group GS + HA than those in group placebo + HA. CONCLUSIONS Both strategies alleviated symptoms in short term, but the patients treated with GS benefited more than those with placebo in long term, which may be due to the suppression of IL-1β and IL-6 and the stimulation of TGF-β.
Collapse
Affiliation(s)
- Xiao Cen
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology (Sichuan University), Chengdu, Sichuan, China.,Department of Oral and Maxillofacial Surgery, West China College of Stomatology (Sichuan University), Chengdu, Sichuan, China
| | - Yan Liu
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology (Sichuan University), Chengdu, Sichuan, China.,Department of Oral and Maxillofacial Surgery, West China College of Stomatology (Sichuan University), Chengdu, Sichuan, China
| | - Shasha Wang
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology (Sichuan University), Chengdu, Sichuan, China.,Department of Oral and Maxillofacial Surgery, West China College of Stomatology (Sichuan University), Chengdu, Sichuan, China
| | - Xianrui Yang
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology (Sichuan University), Chengdu, Sichuan, China.,Department of Orthodontics, West China College of Stomatology (Sichuan University), Chengdu, Sichuan, China
| | - Zongdao Shi
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology (Sichuan University), Chengdu, Sichuan, China.,Department of Oral and Maxillofacial Surgery, West China College of Stomatology (Sichuan University), Chengdu, Sichuan, China
| | - Xinhua Liang
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology (Sichuan University), Chengdu, Sichuan, China.,Department of Oral and Maxillofacial Surgery, West China College of Stomatology (Sichuan University), Chengdu, Sichuan, China
| |
Collapse
|
12
|
Sanders M, Ball PA, Morrissey H. Re: Consumers Report Value of Glucosamine for Rheumatoid Arthritis. J Altern Complement Med 2017; 23:823. [PMID: 28849945 DOI: 10.1089/acm.2017.0150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Marcus Sanders
- 1 School of Psychological and Clinical Sciences, Faculty of Engineering, Health, Science and the Environment, Charles Darwin University , Darwin, Australia
| | - Patrick A Ball
- 2 School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton , Wolverhampton, United Kingdom
| | - Hana Morrissey
- 2 School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton , Wolverhampton, United Kingdom
| |
Collapse
|
13
|
Avery RJ, Eisenberg MD, Cantor JH. An examination of structure-function claims in dietary supplement advertising in the U.S.: 2003-2009. Prev Med 2017; 97:86-92. [PMID: 28115209 DOI: 10.1016/j.ypmed.2017.01.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 01/16/2017] [Accepted: 01/17/2017] [Indexed: 12/31/2022]
Abstract
Dietary supplement advertising cannot claim a causal link between the product and the treatment, prevention, or cure of a disease unless manufacturers seek approval from the FDA for a health claim. Manufacturers can make structure-function (S-F) claims without FDA approval linking a supplement to a body function or system using words such as "may help" or "promotes." These S-F claims are examined in this study in order to determine whether they mimic health claims for which the FDA requires stricter scientific evidence. Data include S-F claims in supplement advertisements (N=6179) appearing in US nationally circulated magazines (N=137) from 2003 to 2009. All advertisements were comprehensively coded for S-F claims, seals of approval, and other claims of guarantee. S-F claims associate supplements with a wide variety of health conditions, many of which are serious diseases and/or ailments. A significant number of the specific verbs used in these S-F claims are indicative of disease treatment/cure effects, thereby possibly mimicking health claims to the average consumer. The strength of the clinical associations made are largely unsubstantiated in the medical literature. Claims that a product is "scientifically proven" or "guaranteed" were largely unsubstantiated by clinical literature. Ads carrying externally validating seals of approval were highly prevalent. S-F claims that strongly mimic FDA-prohibited health claims are likely to create confusion in interpretation and possible public health concerns are discussed.
Collapse
Affiliation(s)
- Rosemary J Avery
- Department of Policy Analysis and Management, Cornell University, Ithaca, NY 14853, United States.
| | - Matthew D Eisenberg
- Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD 21205, United States.
| | - Jonathan H Cantor
- Wagner School of Public Service, New York University, New York, NY 10012, United States.
| |
Collapse
|
14
|
Harrison-Muñoz S, Rojas-Briones V, Irarrázaval S. Is glucosamine effective for osteoarthritis? Medwave 2017; 17:e6867. [DOI: 10.5867/medwave.2017.6867] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 12/27/2016] [Indexed: 11/27/2022] Open
|
15
|
Maricar N, Callaghan MJ, Parkes MJ, Felson DT, O'Neill TW. Interobserver and Intraobserver Reliability of Clinical Assessments in Knee Osteoarthritis. J Rheumatol 2016; 43:2171-2178. [PMID: 27909143 DOI: 10.3899/jrheum.150835] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2016] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Clinical examination of the knee is subject to measurement error. The aim of this analysis was to determine interobserver and intraobserver reliability of commonly used clinical tests in patients with knee osteoarthritis (OA). METHODS We studied subjects with symptomatic knee OA who were participants in an open-label clinical trial of intraarticular steroid therapy. Following standardization of the clinical test procedures, 2 clinicians assessed 25 subjects independently at the same visit, and the same clinician assessed 88 subjects over an interval period of 2-10 weeks; in both cases prior to the steroid intervention. Clinical examination included assessment of bony enlargement, crepitus, quadriceps wasting, knee effusion, joint-line and anserine tenderness, and knee range of movement (ROM). Intraclass correlation coefficients (ICC), estimated kappa (κ), weighted kappa (κω), and Bland-Altman plots were used to determine interobserver and intraobserver levels of agreement. RESULTS Using Landis and Koch criteria, interobserver κ scores were moderate for patellofemoral joint (κ = 0.53) and anserine tenderness (κ = 0.48); good for bony enlargement (κ = 0.66), quadriceps wasting (κ = 0.78), crepitus (κ = 0.78), medial tibiofemoral joint tenderness (κ = 0.76), and effusion assessed by ballottement (κ = 0.73) and bulge sign (κω = 0.78); and excellent for lateral tibiofemoral joint tenderness (κ = 1.00), flexion (ICC = 0.97), and extension (ICC = 0.87) ROM. Intraobserver κ scores were moderate for lateral tibiofemoral joint tenderness (κ = 0.60); good for crepitus (κ = 0.78), effusion assessed by ballottement test (κ = 0.77), patellofemoral joint (κ = 0.66), medial tibiofemoral joint (κ = 0.64), and anserine tenderness (κ = 0.73); and excellent for effusion assessed by bulge sign (κω = 0.83), bony enlargement (κ = 0.98), quadriceps wasting (κ = 0.83), flexion (ICC = 0.99), and extension (ICC = 0.96) ROM. CONCLUSION Among individuals with symptomatic knee OA, the reliability of clinical examination of the knee was at least good for the majority of clinical signs of knee OA.
Collapse
Affiliation(s)
- Nasimah Maricar
- From the Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre (MAHSC), University of Manchester; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service (NHS) Foundation Trust, MAHSC, Manchester; Department of Physiotherapy, and Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK; Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA. .,N. Maricar, BSc (Hons), MSc, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Physiotherapy, Salford Royal NHS Foundation Trust; M.J. Callaghan, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; M.J. Parkes, BSc (Hons), Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; D.T. Felson, MD, MPH, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Clinical Epidemiology Unit, Boston University School of Medicine; T.W. O'Neill, MB, BCh, BAO, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Rheumatology, Salford Royal NHS Foundation Trust.
| | - Michael J Callaghan
- From the Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre (MAHSC), University of Manchester; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service (NHS) Foundation Trust, MAHSC, Manchester; Department of Physiotherapy, and Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK; Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA.,N. Maricar, BSc (Hons), MSc, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Physiotherapy, Salford Royal NHS Foundation Trust; M.J. Callaghan, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; M.J. Parkes, BSc (Hons), Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; D.T. Felson, MD, MPH, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Clinical Epidemiology Unit, Boston University School of Medicine; T.W. O'Neill, MB, BCh, BAO, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Rheumatology, Salford Royal NHS Foundation Trust
| | - Matthew J Parkes
- From the Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre (MAHSC), University of Manchester; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service (NHS) Foundation Trust, MAHSC, Manchester; Department of Physiotherapy, and Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK; Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA.,N. Maricar, BSc (Hons), MSc, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Physiotherapy, Salford Royal NHS Foundation Trust; M.J. Callaghan, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; M.J. Parkes, BSc (Hons), Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; D.T. Felson, MD, MPH, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Clinical Epidemiology Unit, Boston University School of Medicine; T.W. O'Neill, MB, BCh, BAO, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Rheumatology, Salford Royal NHS Foundation Trust
| | - David T Felson
- From the Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre (MAHSC), University of Manchester; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service (NHS) Foundation Trust, MAHSC, Manchester; Department of Physiotherapy, and Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK; Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA.,N. Maricar, BSc (Hons), MSc, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Physiotherapy, Salford Royal NHS Foundation Trust; M.J. Callaghan, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; M.J. Parkes, BSc (Hons), Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; D.T. Felson, MD, MPH, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Clinical Epidemiology Unit, Boston University School of Medicine; T.W. O'Neill, MB, BCh, BAO, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Rheumatology, Salford Royal NHS Foundation Trust
| | - Terence W O'Neill
- From the Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre (MAHSC), University of Manchester; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service (NHS) Foundation Trust, MAHSC, Manchester; Department of Physiotherapy, and Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK; Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA.,N. Maricar, BSc (Hons), MSc, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Physiotherapy, Salford Royal NHS Foundation Trust; M.J. Callaghan, PhD, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; M.J. Parkes, BSc (Hons), Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC; D.T. Felson, MD, MPH, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Clinical Epidemiology Unit, Boston University School of Medicine; T.W. O'Neill, MB, BCh, BAO, Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, MAHSC, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, MAHSC, and Department of Rheumatology, Salford Royal NHS Foundation Trust
| |
Collapse
|
16
|
Nahin RL, Boineau R, Khalsa PS, Stussman BJ, Weber WJ. Evidence-Based Evaluation of Complementary Health Approaches for Pain Management in the United States. Mayo Clin Proc 2016; 91:1292-306. [PMID: 27594189 PMCID: PMC5032142 DOI: 10.1016/j.mayocp.2016.06.007] [Citation(s) in RCA: 127] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 06/15/2016] [Accepted: 06/21/2016] [Indexed: 12/25/2022]
Abstract
Although most pain is acute and resolves within a few days or weeks, millions of Americans have persistent or recurring pain that may become chronic and debilitating. Medications may provide only partial relief from this chronic pain and can be associated with unwanted effects. As a result, many individuals turn to complementary health approaches as part of their pain management strategy. This article examines the clinical trial evidence for the efficacy and safety of several specific approaches-acupuncture, manipulation, massage therapy, relaxation techniques including meditation, selected natural product supplements (chondroitin, glucosamine, methylsulfonylmethane, S-adenosylmethionine), tai chi, and yoga-as used to manage chronic pain and related disability associated with back pain, fibromyalgia, osteoarthritis, neck pain, and severe headaches or migraines.
Collapse
Affiliation(s)
- Richard L Nahin
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD.
| | - Robin Boineau
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD
| | - Partap S Khalsa
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD
| | - Barbara J Stussman
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD
| | - Wendy J Weber
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD
| |
Collapse
|
17
|
Davidson RK, Clark IM. Dietary intervention for osteoarthritis: Clinical trials after the ‘
B
one and
J
oint
D
ecade’. NUTR BULL 2015. [DOI: 10.1111/nbu.12154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
18
|
Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res 2015; 20:24. [PMID: 25889669 PMCID: PMC4359794 DOI: 10.1186/s40001-015-0115-7] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 02/23/2015] [Indexed: 01/06/2023] Open
Abstract
Background To conduct a systematic review and network meta-analysis of randomized controlled trials (RCTs) with the aims of comparing relevant clinical outcomes (that is, visual analog scores (VAS), total and sub-Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) scores, Lequesne algofunctional index, joint space width change, and adverse events) between diacerein, glucosamine, and placebo. Methods Medline and Scopus databases were searched from inception to 29 August 2014, using PubMed and Scopus search engines and included RCTs or quasi-experimental designs comparing clinical outcomes between treatments. Data were extracted from original studies. A network meta-analysis was performed by applying weight regression for continuous outcomes and a mixed-effect Poisson regression for dichotomous outcomes. Results Thirty-one of 505 identified studies were eligible. Compared to placebo, glucosamine showed a significant improvement with unstandardized mean differences (UMD) in total WOMAC, pain WOMAC, function WOMAC, and Lequesne score of −2.49 (95% confidence interval (CI) −4.14, −0.83), −0.75 (95% CI: −1.18, −0.32), −4.78 (95% CI: −5.96, −3.59), and −1.03 (95% CI: −1.34, −0.72), respectively. Diacerein clinically improves visual analog scores, function WOMAC, and stiffness WOMAC with UMD values of −2.23 (95% CI: −2.82, −1.64), −6.64 (95% CI: −10.50, −2.78), and −0.68 (95% CI: −1.20, −0.16) when compared to placebo. Conclusions The network meta-analysis suggests that diacerein and glucosamine are equally efficacious for symptom relief in knee OA, but that the former has more side effects. Electronic supplementary material The online version of this article (doi:10.1186/s40001-015-0115-7) contains supplementary material, which is available to authorized users.
Collapse
|
19
|
Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014; 78:184-7. [DOI: 10.1016/j.maturitas.2014.04.015] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 04/12/2014] [Indexed: 10/25/2022]
|
20
|
Green JA, Hirst-Jones KL, Davidson RK, Jupp O, Bao Y, MacGregor AJ, Donell ST, Cassidy A, Clark IM. The potential for dietary factors to prevent or treat osteoarthritis. Proc Nutr Soc 2014; 73:278-88. [PMID: 24572502 DOI: 10.1017/s0029665113003935] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Osteoarthritis (OA) is a degenerative joint disease for which there are no disease-modifying drugs. It is a leading cause of disability in the UK. Increasing age and obesity are both major risk factors for OA and the health and economic burden of this disease will increase in the future. Focusing on compounds from the habitual diet that may prevent the onset or slow the progression of OA is a strategy that has been under-investigated to date. An approach that relies on dietary modification is clearly attractive in terms of risk/benefit and more likely to be implementable at the population level. However, before undertaking a full clinical trial to examine potential efficacy, detailed molecular studies are required in order to optimise the design. This review focuses on potential dietary factors that may reduce the risk or progression of OA, including micronutrients, fatty acids, flavonoids and other phytochemicals. It therefore ignores data coming from classical inflammatory arthritides and nutraceuticals such as glucosamine and chondroitin. In conclusion, diet offers a route by which the health of the joint can be protected and OA incidence or progression decreased. In a chronic disease, with risk factors increasing in the population and with no pharmaceutical cure, an understanding of this will be crucial.
Collapse
Affiliation(s)
- Jonathan A Green
- School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
| | | | - Rose K Davidson
- School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
| | - Orla Jupp
- School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
| | - Yongping Bao
- Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK
| | | | - Simon T Donell
- Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK
| | - Aedín Cassidy
- Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK
| | - Ian M Clark
- School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
| |
Collapse
|
21
|
Zhang L, Gao YY, Lv XJ. Letter regarding article by Wu et al., 'efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials'. Int J Clin Pract 2013; 67:1359-60. [PMID: 24246217 DOI: 10.1111/ijcp.12250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2013] [Accepted: 07/09/2013] [Indexed: 02/05/2023] Open
Affiliation(s)
- L Zhang
- Center of Infectious Disease, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
| | | | | |
Collapse
|